299 related articles for article (PubMed ID: 15867241)
1. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
2. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP
Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
4. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
5. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Tentori L; Portarena I; Torino F; Scerrati M; Navarra P; Graziani G
Glia; 2002 Oct; 40(1):44-54. PubMed ID: 12237842
[TBL] [Abstract][Full Text] [Related]
7. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M; Middleton MR; Bridgewater J; Lee SM; Dawson M; Jowle D; Halbert G; Waller S; McGrath H; Gumbrell L; McElhinney RS; Donnelly D; McMurry TB; Margison GP
Clin Cancer Res; 2006 Mar; 12(5):1577-84. PubMed ID: 16533784
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide.
Tentori L; Orlando L; Lacal PM; Benincasa E; Faraoni I; Bonmassar E; D'Atri S; Graziani G
Mol Pharmacol; 1997 Aug; 52(2):249-58. PubMed ID: 9271347
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
Lee SM; Thatcher N; Crowther D; Margison GP
Br J Cancer; 1994 Mar; 69(3):452-6. PubMed ID: 8123472
[TBL] [Abstract][Full Text] [Related]
10. Recent approaches to improve the antitumor efficacy of temozolomide.
Tentori L; Graziani G
Curr Med Chem; 2009; 16(2):245-57. PubMed ID: 19149575
[TBL] [Abstract][Full Text] [Related]
11. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Philip PA; Souliotis VL; Harris AL; Salisbury A; Tates AD; Mitchell K; van Delft JH; Ganesan TS; Kyrtopoulos SA
Clin Cancer Res; 1996 Feb; 2(2):303-10. PubMed ID: 9816173
[TBL] [Abstract][Full Text] [Related]
12. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.
Tentori L; Portarena I; Vernole P; De Fabritiis P; Madaio R; Balduzzi A; Roy R; Bonmassar E; Graziani G
Cancer Chemother Pharmacol; 2001 Apr; 47(4):361-9. PubMed ID: 11345654
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide: mechanisms of action, repair and resistance.
Zhang J; Stevens MF; Bradshaw TD
Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
[TBL] [Abstract][Full Text] [Related]
14. Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines.
Maynard K; Parsons PG; Cerny T; Margison GP
Cancer Res; 1989 Sep; 49(17):4813-7. PubMed ID: 2547518
[TBL] [Abstract][Full Text] [Related]
15. O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
Fontijn D; Adema AD; Bhakat KK; Pinedo HM; Peters GJ; Boven E
Mol Cancer Ther; 2007 Oct; 6(10):2807-15. PubMed ID: 17938272
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Plummer R; Jones C; Middleton M; Wilson R; Evans J; Olsen A; Curtin N; Boddy A; McHugh P; Newell D; Harris A; Johnson P; Steinfeldt H; Dewji R; Wang D; Robson L; Calvert H
Clin Cancer Res; 2008 Dec; 14(23):7917-23. PubMed ID: 19047122
[TBL] [Abstract][Full Text] [Related]
17. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Middleton MR; Lunn JM; Morris C; Rustin G; Wedge SR; Brampton MH; Lind MJ; Lee SM; Newell DR; Bleehen NM; Newlands ES; Calvert AH; Margison GP; Thatcher N
Br J Cancer; 1998 Nov; 78(9):1199-202. PubMed ID: 9820180
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
19. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Middleton MR; Kelly J; Goodger S; Thatcher N; Margison GP
Cancer Chemother Pharmacol; 2000; 45(1):15-20. PubMed ID: 10647496
[TBL] [Abstract][Full Text] [Related]
20. In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.
Lee SM; Thatcher N; Crowther D; Margison GP
Cancer Chemother Pharmacol; 1992; 31(3):240-6. PubMed ID: 1464162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
